EC grants marketing authorisation for Jyseleca to treat adults with moderate to severe active rheumatoid arthritis

This article was originally published here

RA is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.2 Almost 3 million people in Europe are

The post EC grants marketing authorisation for Jyseleca to treat adults with moderate to severe active rheumatoid arthritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply